CR20210489A - Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento - Google Patents
Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamentoInfo
- Publication number
- CR20210489A CR20210489A CR20210489A CR20210489A CR20210489A CR 20210489 A CR20210489 A CR 20210489A CR 20210489 A CR20210489 A CR 20210489A CR 20210489 A CR20210489 A CR 20210489A CR 20210489 A CR20210489 A CR 20210489A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmaceutical composition
- variant
- human
- drug
- present
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 title 1
- 238000010254 subcutaneous injection Methods 0.000 title 1
- 239000007929 subcutaneous injection Substances 0.000 title 1
- 101100178973 Homo sapiens SPAM1 gene Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a una composición farmacéutica que incluye (a) un medicamento y (b) una variante PH20 humana. La variante de la PH20 humana incluida en la composición farmacéutica según la presente divulgación incluye sustitución (es) de residuos de aminoácidos en una o mas regiones seleccionadas de una región de la hélice alfa 8 (S347 a C381) y una región de enlace (A333 a R346) entre la hélice alfa 7 y la hélice alfa 8 en la PH20 humana de tipo salvaje que tiene la secuencia de aminoácidos de SEC ID NO: 1, en la que el (los) residuo (s) de aminoácidos situado (s) en la N-terminal o la C-terminal se escinde (n) selectivamente. Además, la composición farmacéutica según la presente divulgación puede incluir además un aditivo farmacéuticamente aceptable, en particular un estabilizador. La composición farmacéutica según la presente divulgación puede maximizar el efecto terepéutico de un medicamento utilizado en combinación con la misma, debido al efecto de las variantes humanas PH20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190033880 | 2019-03-25 | ||
| PCT/KR2020/003975 WO2020197230A1 (ko) | 2019-03-25 | 2020-03-24 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210489A true CR20210489A (es) | 2021-12-07 |
Family
ID=72611090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210489A CR20210489A (es) | 2019-03-25 | 2020-03-24 | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20210363270A1 (es) |
| EP (2) | EP4461811A2 (es) |
| JP (3) | JP7295150B2 (es) |
| KR (3) | KR102507853B1 (es) |
| CN (3) | CN116870164B (es) |
| AU (2) | AU2020248612B9 (es) |
| BR (1) | BR112021019076A2 (es) |
| CA (1) | CA3131052A1 (es) |
| CL (1) | CL2021002464A1 (es) |
| CO (1) | CO2021012380A2 (es) |
| CR (1) | CR20210489A (es) |
| DO (1) | DOP2021000197A (es) |
| EA (1) | EA202192588A1 (es) |
| EC (1) | ECSP21070640A (es) |
| IL (1) | IL286539A (es) |
| JO (1) | JOP20210262A1 (es) |
| MX (1) | MX2021011278A (es) |
| NI (1) | NI202100085A (es) |
| PE (1) | PE20220283A1 (es) |
| SA (1) | SA521430398B1 (es) |
| SG (1) | SG11202110512WA (es) |
| WO (1) | WO2020197230A1 (es) |
| ZA (2) | ZA202108027B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3130347T1 (sl) | 2011-12-30 | 2020-02-28 | Halozyme, Inc. | Variante polipeptida PH20, formulacije in uporabe le-teh |
| LT3448391T (lt) | 2016-04-27 | 2024-06-25 | AbbVie Manufacturing Management Unlimited Company | Ligų, kurių atveju il-13 aktyvumas yra žalingas, gydymo būdas, panaudojant anti-il-13 antikūnus |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| JOP20200275A1 (ar) | 2018-05-10 | 2020-11-02 | Regeneron Pharma | صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز |
| CN111971387A (zh) * | 2018-07-25 | 2020-11-20 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| CA3137324A1 (en) * | 2020-01-23 | 2021-07-29 | Alteogen, Inc. | Novel hyaluronidase variants with improved stability and pharmaceutical composition containing the same |
| AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
| JP2024503265A (ja) | 2020-12-28 | 2024-01-25 | ブリストル－マイヤーズ スクイブ カンパニー | 抗体組成物およびその使用の方法 |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| JP2024530152A (ja) | 2021-08-02 | 2024-08-16 | アルジェニクス ビーブイ | 皮下単位剤形 |
| JP2024535021A (ja) | 2021-09-14 | 2024-09-26 | 武田薬品工業株式会社 | ヒアルロニダーゼを用いた濃縮抗体製剤の容易化された送達 |
| AU2022376750A1 (en) * | 2021-10-29 | 2024-05-16 | Alteogen Inc. | Pharmaceutical composition comprising human hyaluronidase ph20 and drug |
| WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| MX2024009994A (es) * | 2022-03-07 | 2024-08-22 | Mabxience Res S L | Formulaciones estables para anticuerpos. |
| KR20230150203A (ko) * | 2022-04-20 | 2023-10-30 | 주식회사 알토스바이오로직스 | 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도 |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN118401661A (zh) * | 2022-06-22 | 2024-07-26 | 阿特根公司 | N-末端和/或c-末端切割的可溶性ph20多肽及其用途 |
| WO2024005502A1 (ko) * | 2022-06-29 | 2024-01-04 | 주식회사 오디스젠 | 중성 ph에서 활성을 나타내는 히알루로니다제 hyal1 변이체 |
| KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
| WO2024117476A1 (ko) * | 2022-11-28 | 2024-06-06 | 주식회사 대웅제약 | 생체이용률이 개선된 니클로사마이드 함유 조성물 |
| KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| WO2024196173A1 (ko) * | 2023-03-23 | 2024-09-26 | (주)알테오젠 | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603541B2 (en) * | 2003-03-05 | 2013-01-23 | Halozyme, Inc. | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| KR20080082628A (ko) | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 수용체 및 리간드 이소형태의 제조 방법 |
| TWI532498B (zh) * | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| NZ588638A (en) * | 2008-04-14 | 2012-09-28 | Halozyme Inc | Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides |
| CA2746181C (en) * | 2008-12-09 | 2016-03-15 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
| US20100305500A1 (en) * | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| SI3130347T1 (sl) * | 2011-12-30 | 2020-02-28 | Halozyme, Inc. | Variante polipeptida PH20, formulacije in uporabe le-teh |
| TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| JP6537076B2 (ja) * | 2014-07-31 | 2019-07-03 | 国立大学法人神戸大学 | 分泌シグナルペプチドならびにそれを利用したタンパク質の分泌および細胞表層提示 |
| HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
| CA3045007A1 (en) * | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| HUE064898T2 (hu) * | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN111971387A (zh) * | 2018-07-25 | 2020-11-20 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
-
2020
- 2020-03-24 KR KR1020227016935A patent/KR102507853B1/ko active IP Right Grant
- 2020-03-24 CA CA3131052A patent/CA3131052A1/en active Pending
- 2020-03-24 EP EP24185844.8A patent/EP4461811A2/en active Pending
- 2020-03-24 US US17/052,952 patent/US20210363270A1/en active Pending
- 2020-03-24 JP JP2020569741A patent/JP7295150B2/ja active Active
- 2020-03-24 CN CN202310416462.0A patent/CN116870164B/zh active Active
- 2020-03-24 CN CN202080003052.8A patent/CN112203642A/zh active Pending
- 2020-03-24 PE PE2021001563A patent/PE20220283A1/es unknown
- 2020-03-24 MX MX2021011278A patent/MX2021011278A/es unknown
- 2020-03-24 EA EA202192588A patent/EA202192588A1/ru unknown
- 2020-03-24 CN CN202310758097.1A patent/CN117100867A/zh active Pending
- 2020-03-24 SG SG11202110512WA patent/SG11202110512WA/en unknown
- 2020-03-24 KR KR1020237007559A patent/KR20230037691A/ko active Search and Examination
- 2020-03-24 CR CR20210489A patent/CR20210489A/es unknown
- 2020-03-24 KR KR1020207030248A patent/KR102650991B1/ko active IP Right Grant
- 2020-03-24 BR BR112021019076A patent/BR112021019076A2/pt unknown
- 2020-03-24 JO JOP/2021/0262A patent/JOP20210262A1/ar unknown
- 2020-03-24 EP EP20776465.5A patent/EP3785701A4/en active Pending
- 2020-03-24 AU AU2020248612A patent/AU2020248612B9/en active Active
- 2020-03-24 WO PCT/KR2020/003975 patent/WO2020197230A1/ko active Application Filing
-
2021
- 2021-09-19 IL IL286539A patent/IL286539A/en unknown
- 2021-09-22 CL CL2021002464A patent/CL2021002464A1/es unknown
- 2021-09-22 EC ECSENADI202170640A patent/ECSP21070640A/es unknown
- 2021-09-22 DO DO2021000197A patent/DOP2021000197A/es unknown
- 2021-09-22 NI NI202100085A patent/NI202100085A/es unknown
- 2021-09-22 CO CONC2021/0012380A patent/CO2021012380A2/es unknown
- 2021-09-24 SA SA521430398A patent/SA521430398B1/ar unknown
- 2021-10-20 ZA ZA2021/08027A patent/ZA202108027B/en unknown
-
2022
- 2022-04-18 JP JP2022068166A patent/JP7166478B2/ja active Active
- 2022-05-13 US US17/744,575 patent/US20220289864A1/en active Pending
- 2022-08-22 ZA ZA2022/09369A patent/ZA202209369B/en unknown
-
2023
- 2023-02-24 JP JP2023026863A patent/JP2023078146A/ja active Pending
-
2024
- 2024-02-23 AU AU2024201238A patent/AU2024201238A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011278A (es) | Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un farmaco. | |
| AU2019311658A8 (en) | Novel hyaluronidase variants and pharmaceutical composition comprising the same | |
| MX2022008060A (es) | Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. | |
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| MXPA01007956A (es) | Polipeptido antimicrobiano/neutralizador de endotoxina. | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| HK1089788A1 (en) | A recombinant protein with cancer suppression action, its encoding gene and use | |
| PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
| MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
| NZ614557A (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
| MX2021009696A (es) | Vectores de genoterapia para el tratamiento de la enfermedad de danon. | |
| CR20220206A (es) | Agonistas del receptor npy2 | |
| MX2021013743A (es) | Subunidad s1 modificada de la proteina de espicula de coronavirus. | |
| WO2004009625A3 (en) | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES | |
| MX2024005173A (es) | Composicion farmaceutica que comprende hialuronidasa humana ph20 y farmaco. | |
| MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
| MX2023001532A (es) | Agonistas del receptor npy2 solubles. | |
| MX2022003598A (es) | Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
| MX2022008748A (es) | Administración oral de péptidos. | |
| MX2020012532A (es) | Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). | |
| MX2022013550A (es) | Composiciones y metodos para suministrar agentes farmaceuticamente activos. | |
| WO2022157747A3 (en) | Pharmaceutical glp peptide compositions and methods of preparation thereof |